<DOC>
	<DOC>NCT02659631</DOC>
	<brief_summary>The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.</brief_summary>
	<brief_title>PF-06671008 Dose Escalation Study in Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Key Inclusion Criteria Diagnosis of tumor type with the potential to have Pcadherin expression that is resistant to standard therapy or for which no standard therapy is available Performance status of 0 or 1 Adequate bone marrow, kidney and liver function Key Exclusion Criteria Known CNS disease including, but not limited to, metastases Current or history of seizure disorder History of or active autoimmune disorders Active bacterial, fungal or viral infection Major surgery, anticancer therapy, or radiation therapy within 4 weeks of study treatment Requirement for systemic immune suppressive medication Grade 2 or greater peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>P-cadherin</keyword>
	<keyword>PF-06671008</keyword>
	<keyword>solid tumors</keyword>
	<keyword>lung cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>TNBC</keyword>
	<keyword>CRC</keyword>
	<keyword>neoplasms</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>